Abstract 1359
Background
Across the most commonly diagnosed cancers (breast, colorectal, lung and prostate), advances in curative treatment have led to improvements in cancer survival. Workplace policies for medical leave however, may have been instituted when surgery alone was sufficient treatment for cancer. The duration of adjuvant therapy may not be incorporated into laws providing temporary financial assistance or protecting patients from workplace dismissal. Our objective is to determine the median duration of curative treatment and recovery time for the four common cancers and to understand the implications in the broader context.
Methods
BC Cancer provides cancer care for a population of 4.6 million. A retrospective review was completed of referred patients from 2010-2016, ≤ 65 years old, newly diagnosed with stage I-III breast, colorectal, lung, prostate cancer, received curative intent treatment that includes either chemotherapy or radiotherapy. Information was collected on baseline characteristics, date of diagnosis, surgical procedure and date, radiotherapy type, duration and intent (neoadjuvant/ concurrent/ adjuvant), chemotherapy type, duration and intent.
Results
26,995 patients were included in the study, 11,911 (44%) received definitive radiotherapy or multimodality treatment.Table: 1655P
Breast N = 12706 | Prostate N = 6360 | Colorectal N = 5336 | Lung N = 2593 | |
---|---|---|---|---|
No adjuvant treatment | 4605 | 5377 | 3491 | 1611 |
Definitive radiation or multimodality treatment | 8101 | 983 | 1845 | 982 |
Median time from diagnosis to definitive treatment (weeks) | 5.14 | 13.71 | 4.29 | 5.42 |
Median time between definitive treatment and adjuvant therapy (weeks) | 8.14 | 18.14 | 8.42 | 8.57 |
Median duration of adjuvant chemotherapy (weeks) | 14.29 | N/A | 20.00 | 10.00 |
Median duration of adjuvant radiation +/- chemotherapy (weeks) | 3.85 | 6.71 | 5.00 | 5.57 |
Median duration of definitive radiation +/- chemotherapy (weeks) | N/A | 6.42 | N/A | 6.42 |
Median duration from definitive treatment to completion of all treatment (weeks) | 23.57 | 6.85 | 28.29 | 18.00/6.14* *chemo/xrt |
Conclusions
Almost half of patients who undergo curative cancer treatment require definitive radiotherapy or multimodality treatment. The median duration of therapy varies widely depending on primary site and modality (6.14 - 28.29 weeks). This has implications for financial support such as United Kingdom’s Statutory Sick Pay (28 weeks) and Canada Employment Insurance (15 weeks), as well as workplace dismissal in the United States where the Family and Medical Leave Act protects employees for 12 weeks absence. Governments should consider amending the laws to reflect current cancer treatment durations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
C. Ho: Honoraria (self), Research grant / Funding (self): AstraZeneca; Honoraria (self), Research grant / Funding (self), Travel / Accommodation / Expenses: Boehringer Ingelheim; Honoraria (self), Travel / Accommodation / Expenses: Pfizer ; Honoraria (self): BMS; Honoraria (self), Travel / Accommodation / Expenses: Roche; Honoraria (self): Lilly; Research grant / Funding (self): Genzyme; Honoraria (self), Research grant / Funding (self): Eisai; Honoraria (self): Merck; Honoraria (self): Bayer. All other authors have declared no conflicts of interest.
Resources from the same session
2927 - Singapore Caregiver Quality Of Life Scale (SCQOLS): Turkish Validity and Reliability Study
Presenter: Nur Basak
Session: Poster Display session 3
Resources:
Abstract
5066 - Screening for Psicosocial Distress in recently diagnosed cancer patients
Presenter: Eva Baillès
Session: Poster Display session 3
Resources:
Abstract
6074 - Socio-demographic characteristics and quality of life analysis of cancer survivors followed at a Primary Care Center.
Presenter: Begona Grana Suarez
Session: Poster Display session 3
Resources:
Abstract
5129 - The adhesion in the screening measures in carrying patients of breast cancer and ovary hereditary and the relationship with the psychological aspects
Presenter: Melinda Concepcion
Session: Poster Display session 3
Resources:
Abstract
5635 - Assessment of emotional discomfort of oncological patients in the first nursing visit at Donostia University Hospital
Presenter: Elena Uranga
Session: Poster Display session 3
Resources:
Abstract
858 - A systematic review and meta-analysis of the distress thermometer for the screening of distress in Chinese patients with cancer
Presenter: Hui Hui Sun
Session: Poster Display session 3
Resources:
Abstract
4475 - Pharmacist and Nurse (PN) Led Melanoma Immunotherapy Clinic: Patient Experience Survey
Presenter: Dharmisha Chauhan
Session: Poster Display session 3
Resources:
Abstract
1871 - Phone Triage & Acute Review Clinics: The emerging role of the Oncology Specialist Nurse
Presenter: Fiona Barrett
Session: Poster Display session 3
Resources:
Abstract
5193 - Patient reported outcomes during immunotherapy: symptom burden in daily clinical practice
Presenter: José Koldenhof
Session: Poster Display session 3
Resources:
Abstract
2453 - Factors related to hospital length of stay, re-admissions and unplanned care for patients with cancer, an on-going study
Presenter: Helena Ullgren
Session: Poster Display session 3
Resources:
Abstract